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Cyclosporine enhances the expression of TGF-f3 in the
juxtaglomerular cells of the rat kidney
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Cyclosporine enhances the expression of TGF.I3 in the juxtaglomerular
cells of the rat kidney. The mediators of cyclosporine (C5A) nephrotox-
icity remain ill defined. In this study, we describe evidence of increased
amounts of transforming growth factor-beta (TGF-j3) in the kidneys of
adult male Wistar rats treated with CsA (5 to 25 mg/kg/day) for four
weeks. Localization of TGF-/3 was undertaken immunocytochemically at
both light and electron microscope levels and Northern blot analysis was
applied to detect changes in transcription of TGF-f3. In control rats, weak
to moderate immunostaining for TGF-p was observed, in the juxtaglo-
merular arterioles. CsA treatment resulted in a dose-dependent increase
in the number of stained afferent and interlobular arterioles and in the
intensity of staining. The number of stained afferent arterioles increased
from a control value of 0.21 0.08/mm2 cortex to 0.84 0.15/mm2 cortex,
P < 0.01, and to 1.12 0.10/mm2 cortex, P < 0.01, in rats treated with CsA
12.5 mg/kg/day and 25 mg/kg/day, respectively. The number of interlobular
arterioles stained for TGF-13 increased from a control value of 0.07
0.05/mm2 to 0.31 0.02/mm2, P < 0.05, and 0.39 0.07/mm2, P < 0.01,
in rats treated with CsA, 12.5 mg/kg/day and 25 mg/kg/day, respectively. At
the electron microscope level, TGF-13 was localized exclusively within the
granular cells of the juxtaglomerular arterioles. Northern blot analysis
suggested that this enhanced staining is due to increased transcription of
TGF-131. We have therefore observed an association between TGF-13 and
CsA-induced nephrotoxicity. While this does not establish a causal link, it
leads us to postulate that TGF-13, alone or in combination with other
growth factors, may play a role in the pathogenesis of CsA induced
nephrotoxicity.
There is no doubt that the success of solid organ transplantation
over the last decade is due to the introduction of cyclosporine
(CsA) [1—31. Despite this improvement in allograft and patient
survival, the use of CsA is tempered by its nephrotoxic side effects
[4—6]. CsA nephrotoxicity can be identified by acute functional
effects and chronic histological changes. Functional changes in-
clude increased renal vascular resistance and decreased renal
plasma flow and glomerular filtration [7—9]. Chronic structural
changes are marked by arteriolopathy, tubular atrophy and inter-
stitial fibrosis [10]. The mechanism and mediators of these
hemodynamic and structural changes are ill defined, and possible
links between functional changes and structural damage remain to
be elucidated.
A wide range of mediators have been implicated in the acute
hemodynamic effects of CsA, including angiotensin II [7, 11, 12],
an activated sympathetic nervous system [7, 11, 13], thromboxane
A2 [14—16], endothelin [17—19], and most recently, changes in the
nitric oxide system [20—22].
We have recently reported the presence of immunoreactive
platelet-derived growth factor (PDGF) in the renal cortical arte-
rioles of rats injected with nephrotoxic doses of CsA and sug-
gested that PDGF, with its inherent vasoconstrictive and fibro-
genic effects may be involved in the pathogenesis of CsA-induced
nephrotoxicity [23]. Furthermore, the ultrastructural localization
of PDGF within hypertrophied juxtaglomerular cells suggest that
it may also mediate the hypertrophy of the juxtaglomerular cells
which is seen in animals treated with nephrotoxic doses of CsA
[24].
Transforming growth factor-beta (TGF-p) has been shown to
be increased in other experimental models of juxtaglomerular cell
hypertrophy, including that caused by water deprivation [25] and
potassium depletion in rodents [26], and in infants with renal
ischemia [271. These findings, together with the known mitogenic
effect of TGF-/3 on vascular smooth muscle cells, have led to the
hypothesis that TGF-p is involved in hypertrophy of the juxtaglo-
merular cells observed in these conditions.
The observations described above and the frequent co-localiza-
tion of PDGF and TGF-j3 in mesenchymal cells have prompted us
to investigate the changes in juxtaglomerular TGF-13 in the
kidneys of rats treated with CsA.
Methods
Animals
Adult male Wistar rats (Sheffield University strain) weighing
250 to 300 g at the outset of the experiments were housed two to
three to a cage and maintained at 20°C and 45% humidity on a
12-hour light/dark cycle. They were allowed free access to stan-
dard rat chow (Labsure, March, Cambridge, UK) and water,
except one group of pair-fed animals (see below). All procedures
were carried out under licence according to regulations laid down
by Her Majesty's Government, United Kingdom (Animals Scien-
tific Procedures Act, 1986).
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Drug preparation
Cyclosporine (CsA) was a gift of Sandoz UK Ltd. (Cambridge,
UK). It was dissolved first in ethanol (1 g/ml) and then diluted
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with olive oil (low acidity, Sigma, Poole, UK) to a concentration of
10 mg/mI.
Experimental protocols
Rats were injected intraperitoneally with 5, 7.5, 10 mg CsAJkg
body wt (N = 3 per dose), 12.5 or 25 mg CsAJkg body wt (N = 6
perdose), daily for four weeks. Control animals (N = 3 to 6) were
injected with an equivalent volume of the olive oil vehicle. The
food and water consumption of these rats was measured over
periods of 24 hours, at weekly intervals.
To test whether the observed changes were secondary to loss of
appetite and/or dehydration, a group of rats (N = 6) was injected
with 25 mg/kg/day CsA for four weeks, and their daily food and
water consumption was carefully measured. These rats were
placed individually in wire bottomed cages and the average daily
food and water consumption of each rat was measured. The
average of two consecutive days consumption was then given to
the pair fed and watered control rat (N = 6), two days in arrears.
To establish whether the effects of CsA were due to ischemia, a
further group of control rats (N = 6) underwent partial ligation of
the aorta. For this, rats were anaesthetized and the left kidney and
aorta were exposed through a lumbar incision. A silk suture was
then passed around the aorta between the origins of the left and
right renal arteries and tied over a needle stylet of 0.1 mm external
diameter [28]. This resulted in a reproducible reduction in blood
flow to the left kidney. These rats were killed after two weeks.
At the start of the experiment and at sacrifice, all rats were
weighed and placed individually in metabolic cages for 48 hours.
After 24 hours of acclimation, urine was collected over a 24 hour
period for the determination of creatinine clearance rates. Also,
blood samples were withdrawn from the tail vein for the deter-
mination of serum creatinine, potassium and urea concentrations
(standard autoanalyser techniques, Monarch Instruments, UK
Ltd.). Blood levels of CsA were also determined by radioimmu-
noassay [29]. Systolic blood pressure was measured by the tail cuff
method while the rats were lightly anaesthetized with ether.
Tissue preparation
Before sacrifice, the rats were deeply anaesthetized with Sagatal
(Pentobarbitone sodium, RMB Animal Health, Dagenham, UK),
weighed and samples of blood were taken. The kidneys were then
perfused with phosphate buffered saline (PBS) pH 7.2 via a
cannula inserted into the left ventricle of the heart with blood
allowed to drain via a small incision made in the right atrium.
When perfused, the left kidney was cut into 2 to 3 mm thick slices,
weighed and snap frozen with liquid nitrogen for RNA analyses.
The right kidney was processed for light and electron microscope
immunohistochemistry.
For light microscope immunohistochemistry, tissue was fixed
overnight in 4% formol-calcium, dehydrated with alcohol, cleared
with chloroform and embedded in low melting point paraffin wax
(56°C).
For electron microscope immunocytochemistry, tissue was fixed
in 4% wt:vol paraformaldehyde, dehydrated to 50% ethanol at
4°C and then transferred to a deep freeze cabinet at —30°C where
dehydration was completed. Tissues were then embedded and
polymerized at low temperature (—30°C) in Lowicryl HM2O resin
(Agar Scientific, Standstead, UK) as previously described [24].
Light microscope histology
Dewaxed paraffin embedded specimens were routinely stained
with hematoxylin and eosin (H&E), with Masson's trichrome stain
and by the periodic acid-Schiff (PAS) procedure.
Light microscope immunohistochemistty
Sections 4 m thick were mounted on gelatinized glass slides
and stained immunohistochemically by an avidin-biotinylated
horseradish peroxidase procedure, using a commercially available
kit (ABC Elite Kit, Vector Laboratories, Peterborough, UK) as
previously described [23]. Briefly, sections were dewaxed with
xylene and hydrated in graded water:ethanol solutions. Endoge-
nous peroxidase activity was quenched by immersing sections in
0.6% H202 in methanol for 20 minutes and sections were then
incubated for 30 minutes with 1.5% goat or horse serum as
appropriate. Sections were then incubated overnight at 4°C in a
humid atmosphere with a polyclonal rabbit anti-human TGF-f31
and 2 (R & D Systems, Abingdon, UK) or with a mouse
monoclonal anti-smooth muscle actin (anti-a-SMA1), a gift from
Professor G. Gabbiani (Geneva, Switzerland), which specifically
binds to vascular smooth muscle cells [30]. Antibodies were
diluted with phosphate buffered saline (PBS) containing 0.01%
crystalline grade bovine serum albumin (BSA, biotin free, Sigma).
Sections were then incubated with the relevant secondary anti-
body for 30 minutes, rinsed in PBS and incubated with the
peroxidase substrate, 3-amino 9-ethyl carbazole (AEC Kit, Vec-
tor). Finally, sections were counterstained with dilute aqueous
hematoxylin and mounted with Glycergel (Dako, High Wycombe,
UK).
Control incubations involved preadsorption of the antibody
with TGF-f31 and TGF-/32 antigens (R&D Systems, UK), the
substitution of the primary antibody with an equivalent concen-
tration of rabbit or mouse immunoglobulin, as appropriate, or the
omission of the primary antibody.
For evaluation the intensity of staining an arbitrary score from
+ to ++ + was used, where + = weak, + + = moderate, and
+ + + = strong staining.
Light microscope morphometric analysis
The number of juxtaglomerular arteriole profiles stained for
TGF-J3 per mm2 kidney cortex was compared with those stained
with a-SMA1. For this, horizontal serial sections cut through the
hilus of the right kidney of each animal and adjacent sections were
stained for TGF /3 or n-SMA, respectively. Sections were incu-
bated with a-SMA1, which facilitates the identification of glomer-
ular and interlobular arterioles for the morphometric analysis and
for comparison with the TGF-/3 staining. Sections were viewed
down a light microscope fitted with an x 10 flat-field objective, and
the total numbers of glomeruli and stained juxtaglomerular
arterioles were recorded. The cortical area of each of these
sections was measured using a Seescan image analyzer. The
results are expressed as the mean number of glomeruli or stained
juxtaglomerular arterioles per mm2 of kidney cortex.
Electron microscope immunocytochemistiy
Electron microscope immunocytochemical studies were carried
only on tissue from rats treated with CsA (12.5 mg/kg/day) for
four weeks. Ultrathin section (100 nm) were mounted on Collo-
dion-coated nickel grids and incubated with TGF-f3 to demon-
strate its ultrastructural localization, using a Protein A-gold
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Table 1. Body weight gain, blood pressure, blood and serum levels of creatinine, potassium and CsA as well as creatinine clearance of control,
pair-fed control and CsA-treated rats after 1 month of daily injections
N
Body weight
gain
g
Serum creatinine
p.mol/liter
Serum potassium
mmol/liter
Creatinine
clearance rate
ml/min/100 g body wt
Systolic
blood pressure
mm Hg
CsA blood level
ng/ml
Control
CsA, 5 mg/kg
CsA, 7.5 mg/kg
CsA, 10 mg/kg
3
3
3
3
104 1191 4
88 16°
67 7°
35 534 4
39 3°
45 6°
4.9 0.4
4.7 0.3
5.0 0.3
4.9 0.1
0.52 0.03
0.45 0.01
0.46 0.02
0.43 0.04°
118 7
109 5
123 2
121 3
—
423 89
497 155
824 91
Control
CsA, 12.5 mg/kg
6
6
88 5
59 5C
35 2
47 3c
5.8 0.4
4.9 0.1
0.53 0.01
0.29 0.01°
106 9
118 3
—
806 75
Control
CsA, 25 mg/kg
6
6
101 13
42 9°
42 4
71 8°
4.8 0.3
4.8 0.3
0.49 0.03
0.28 0.04
111 7
130 3°
—
3875 484
Pair-fed control
CsA, 25 mg/kg
6
6
74 7
49 6°
48 373 7 5.1 0.35.4 0.4 0.39 0.010.26 0.05° 129 9131 3°
—
2272 106
Results are expressed as mean SEM.
Statistical analysis by one way ANOVA. Differences not significant unless stated otherwise.
ap < 0.05, 'P < 0.01, C< 0.001
labeling procedure [311. Briefly, grids were first inverted succes-
sively on each of the following blocking solutions at room
temperature: (a) PBS containing 0.1% ovalbumin and 0.1%
Tween 20 (POT) for 10 minutes; (b) POT containing 0.1% wt:vol
cold-water fish gelatine (Sigma) for 10 minutes; (c) POT contain-
ing 0.02 M glycine for three minutes. The grids were then
incubated with anti-TGF- diluted (1:40) with POT, overnight at
4°C. The grids were then rinsed with PBS and treated with
Protein-A coupled to 10 nm colloidal gold (Amersham Interna-
tional, Aylesbury, UK, diluted 1:20 with POT) for two hours, at
4°C. Next, the grids were rinsed in PBS and then fixed in 1%
glutaraldehyde for five minutes, at room temperature. Finally, the
grids were rinsed with distilled water and briefly counterstained
with uranyl acetate (5 mm) and lead citrate (2 mm). Sections were
examined in Philips CM1O electron microscope operated at 80 KV
and fitted with 25 mm objective aperture.
Control sections were treated in a similar fashion to that
described for light microscopy immunohistochemistry. In addi-
tion, sections were also incubated with an inappropriate antibody
(polyclonal goat anti-human collagen type IV; Southern Biotech-
nology, Europath, Wales, UK).
RNA analysis
Northern blot analysis was carried on tissues from rats injected
with CsA (12.5 mg/kg/day).
A TGF-f31 specific Kpn, Apa-1 600 bp fragment (amino acids
68 to 268 of the precursor region) of the full length murine
TGF-pl [32] was subcloned in to pBluescribe (Stratagene, UK)
[33]. The 600 bp fragment was excised using a HindIII/EcoRI
digest.
A TGF-f32 specific Pst-1, Sac-I 500 bp fragment (amino acids 81
to 249) of the full length TGF-132 [34] was prepared by PCR [351
and then subcloned into pBluescribe (Stratagene) [33]. The 500
bp fragment was excised using a Pst-1, Sac-i digest. Both the
TGF-131 and TGF-/32 eDNA's were provided by Dr. R. Akhurst
(Duncan Guthrie Institute of Medical Genetics, Glasgow, UK).
Excised cDNA fragments were separated by electrophoresis on
a 1% (wt/vol) agarose TAE gel and then purified from the agarose
using Bandprep (Pharmacia, UK) according to the manufactur-
er's instructions. Twenty-five nanograms of the purified cDNA
were random primed with 32P labeled dCTP (Redivue, Amer-
sham, UK) using the Promega Random Prime System (Promega,
UK). Unincorporated label was removed using Sephadex G50
Nick Columns (Pharmacia) according to the manufacturer's
instructions. For RNA analysis, total RNA was extracted using the
RNAso1 B (Cinnia/Biotex, distributed by Biogenesis, UK) and
quantified by spectrophotometry. Fifteen micrograms of total
RNA were electrophoresed on a 1% agarose MOPS/formalde-
hyde gel and viewed under U.V. light to verify loading and the
presence of intact ribosomal bands. RNA was then transferred to
N nylon (Boehringer Mannheim, UK) by capillary blotting with
20 X SSC. Transferred RNA was cross-linked to the nylon filter
using U.V. irradiation (Stratalinker, Stratagene).
Prehybridization and hybridization were performed as de-
scribed in detail elsewhere [36]. Briefly, filters were prehybridized
in a mixture containing 50% (vol:vol) de-ionized formamide, 5 X
SSPE, 5 1< Denhardt's reagent, 1% (wt:vol) SDS and 200 mg/mI
sonicated and denatured salmon sperm DNA, at 37°C for one
hour. Hybridization was performed under the same conditions
with the addition of labeled probe to 1 X 106 cpm/ml for 18 hours.
Filters were then washed to a stringency of 0.2% SDS/0.2 X SSPE
at 60°C for one hour and then exposed to Kodak XOMAT LS film
for four days with intensifying screens. Developed films were
subsequently analyzed densitometrically using a Seescan image
analyzer. Optical density values for TGF-f3 were standardized by
reference to the optical density of ethidium bromide stained gels
of ribosomal 28 s RNA.
Statistical analysis
Results are expressed as mean SEM. The significance between
groups was determined either by a modified Student's t-test,
Welch test, or by an analysis of variance (ANOVA) with Bonfer-
roni correction for multiple comparisons. In each case, a proba-
bility of less than 5% was taken as significant.
Results
General observations
CsA-treated rats gained weight at a slower rate than control
animals for all doses of the drug including the pair-fed group
(Table 1). There was no significant differences in water consump-
tion between any of the groups. No change in food consumption
was noted with doses of CsA from 5 mg/kg/day to 12.5 mg/kg/day
inclusive. In rats treated with 25 mg/kg/day, food consumption
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declined from 24 g/daylrat at the outset to 18 g/day/rat after seven
days, but remained constant thereafter.
CsA-treated rats showed significantly higher serum creatinine
concentrations after four weeks of treatment when doses of 7.5
mg/kg body wt/day and more were used (Table 1). However,
significant reductions in creatinine clearance were only evident in
those rats treated with 12.5 mg/kg/day or more (Table 1). No
significant difference was observed in serum potassium concentra-
tion between CsA-treated and control rats, for any dose (Table 1).
Whole blood CsA levels increased with the dose of drug and
reached a concentration of 806 75 ng/ml with 12.5 mg/kg/day
CsA and 2272 106 ng/ml with 25 mg/kg/day at the time of
sacrifice (Table 1). Mean systolic blood pressure was only signif-
icantly different from controls in the group treated with the
highest dose of CsA (25 mg/kg/day, Table 1). Equivalent data for
the control group of ischemic animals are shown in Table 2.
Histological changes
When the lower doses of CsA were given (5 to 10 mg/kg/day)
there was little evidence of histological change apart from pro-
nounced PAS staining of some periglomerular and interlobular
arterioles (Fig. 1A). With higher doses (12.5 or 25 mg/kg/day),
strong PAS staining was accompanied by capsular notching and
increased basophilia of the underlying tubules (Fig. 1B). Sections
from rats treated with CsA 25 mg/kg/day stained with Masson's
trichrome stain showed substantial amounts of collagen in the
interstitium of these areas (Fig. IC). Furthermore, some proximal
tubule profiles displayed isometric vacuolation and a few others
appeared either collapsed or dilated (Fig. 1D). However, in all
cases the brush borders appeared intact and no tubular casts were
evident.
In the ischemia group, the ischemic left kidney displayed
proximal tubular vacuolation. Arteriolar hypertrophy and hyali-
nosis were also evident as well as an expansion of the vascular
adventitia. The control right kidney was structurally normal.
Light microscope immunohistochemistty and morphometty
Incubation with the anti-TGF- antibody resulted in the stain-
ing of the juxtaglomerular arterioles and some segments of
interlobular arterioles in CsA-treated rats (Fig. 2 A, B). The size
of the stained areas increased with the dose of CsA up to the level
of 12.5 mg/kg/day. Control tissue also stained with this antibody
but was confined to occasional juxtaglomerular arterioles contain-
ing one or two stained cells (Fig. 2C), with minimal involvement
of the interlobular arterioles.
Staining intensity of tissue from control rats and those injected
with CsA in either a dose of 5 mg/kg/day or 7.5 mg/kg/day was
mostly (—78%) weak with some (—18%) arterioles exhibiting
moderate staining (Table 2). Those rats treated with 10 mg/kg/day
displayed a range of weak to strong staining, while those rats
injected with CsA in doses of 12.5 or 25 mg/kg invariably exhibited
the strongest staining for immunoreactive TGF-/3. (Table 2).
Control sections tested with a non-immune serum (Fig. 2D) or
with antibody pre-adsorbed with the TGF-/31 and those incubated
in the absence of primary antibody showed no specific immuno-
stain.
Rats subjected to renal ischemia showed increased staining for
TGF-p in the left (ischemic) kidney, similar to that seen with CsA
10 mg/kg/day, whereas the right kidney showed a pattern and
intensity of staining similar to control olive oil-treated rats (Fig. 2
E, F).
There was no significant difference between CsA-treated and
control animals in the number of afferent/efferent arterioles per
mm2 of cortex which stained with a-SMA1 (Table 3). However,
the number of profiles which stained with TGF-f3 did increase
following CsA treatment, to 56% and 77% of periglomerular
arterioles (with 12.5 mg/kg/day and 25 mg/kg/day CsA, respec-
tively) compared with only 14% in control animals (Table 3).
There was also a four- to sixfold increase in the number of
interlobular arterioles which stained with TGF-p following CsA
treatment (Table 3). However, the number of arterioles which
stained in pair fed and watered rats was not significantly different
from control values. In rats subjected to renal ischemia, there was
a twofold increase in the number of stained arterioles in the left
ischemic kidney compared to the right control kidney (Table 3),
but there was no significant difference in the number of stained
afferent or interlobular arterioles between the right control kidney
and the other control groups.
Electron microscope immunocytochemistiy
At the electron microscope level, incubation of ultrathin sec-
tions with anti-TGF-/3 followed by Protein A coupled to 10 nm
colloidal gold established that TGF-/3 immunostain was confined
to the secretory granules within the juxtaglomerular cells of the
afferent arterioles (Fig. 3 A, B) and occasional efferent arterioles.
The granules of transformed myocytes in the walls of interlobular
arterioles of CsA-treated rats also stained. Granulated juxtaglo-
merular cells were encountered far less frequently in control
tissue, and usually contained fewer granules. However, these
granules stained for TGF-/3 but generally with a lower density
than seen in CsA-treated tissue (Fig. 3C). No gold particles were
evident over any of the adjoining structures, such as the muscle
wall of the arteriole, the endothelium or the intercellular matrix.
Furthermore, no gold particles were evident when the primary
antibody was substituted by non-immune goat serum (Fig. 3D)
nor when an inappropriate antibody was applied (Fig. 3E). A
similar distribution of gold particles to that of CsA treated rats
was seen in the juxtaglomerular cells of ischemic kidney (Fig. 3F).
Northern blot analysis
Northern blot analysis of total RNA samples from control olive
oil-treated and CsA-treated rat kidney samples showed a single
band of approximately 2.3 kD when probed with the TGF-/31
eDNA (Fig. 4), but no bands were apparent after hybridization
with the TGF-/32 probe. The standardized average optical density
of the TGF-131 bands from CsA-treated samples was significantly
greater than those from control tissue (O.D. 0.073 0.019 vs.
O.D. 0.010 0.003, respectively, P < 0.05) when variations in gel
loading were accounted for by comparison with ribosomal 28 s
RNA.
Discussion
In these studies, we have demonstrated that treatment with CsA
in daily doses ranging from 5 mg/kg/day to 25 mg/kg of body wt
results in an increase in renal immunostaining for TGF-f3. The
staining was most intense at doses of 12.5 mg/kg or higher. We
believe the observed immunostaining to be specific to TGF-pl as
pre-absorption of the antibody with recombinant human TGF-f31
abolished the staining. Northern blot analysis confirmed such an
assertion as an increase in the amount of TGF-131 mRNA and not
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Fig. 1. Histological staining of GsA-treated rat kidney tissue. A. Periglomerular arterioles showing strong PAS staining- CsA, 7.5 mg/kg/day (x 200). B.
Capsular notching and increased basophilia of underlying tubules- CsA, 12.5 mg/kg/day (H & E stains >< 100). C. Section stained with Masson's
trichrome showing subcapsular accumulation of collagen- CsA, 25 mg/kg/day (x 200). D. Proximal tubules showing isometric vacuolation, CsA 25
mg/kg/day (Masson's trichrome >< 200).
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Fig. 2. TGF-f3 immunohistochemist,y. A. CsA-treated (12.5 mg/kg/day) tissue showing intense staining of an hypertrophied afferent arteriole (X 400).
B. CsA-treated (12.5 mg/kg/day) tissue showing strong staining of an interlobular arteriole (X 400). C. Control tissue showing weak staining confined
to a few juxtaglomerular cells of an afferent arteriole (x 400). P. CsA-treated tissue (12.5 mg/kg/day) incubated with antibody preabsorbed with TGF-f31
showing no immunostaining of an hypertrophied afterent arteriole (x 400). E. Tissue from the right (non-ischemic) kidney of a rat subjected to unilateral
renal ischemia demonstrating weak immunostaining of the afferent arteriole (X 400). F. Tissue from the left (ischemic) kidney of a rat subjected to
unilateral ischemia showing moderate immunostaining (X 400).
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Table 2. Body weight gain, blood pressure, serum levels of creatinine
and potassium as well as creatinine clearance of rats subjected to
unilateral ischaemia by partial ligation of the aorta for 2 weeks
Body Creatinine Systolic
weight Serum Serum clearance rate blood
gain creatinine potassium ml/min/100 g pressure
g i.vnol/liter mmol/liter body wt mm Hg
Sham ischemia 31 5 30 2 4.7 0.4 0.53 0.01 106 9
(N =6)
Ischemia 24 12 51 5 4.9 0.6 0.38 0.02 96 12
(N =6)
Results are expressed as mean SEM.
ap <0.05
of TGF-/32 mRNA was noted. At the higher doses of CsA (12.5 to
25 mg/kg/day), there was significant CsA nephrotoxicity associ-
ated with a decline in renal function as well as vascular and
tubular changes. These changes were also associated with hyper-
catabolism [37] as CsA-treated rats showed reduced weight gain
compared to their respective controls.
Morphometric studies showed that although there was no
increase in the frequency of glomerular profiles or a-SMA1-
stained arterioles in CsA-treated rats, there was a significant
increase in the frequency of TGF-J3-positive juxtaglomerular
arterioles. In a previous study, we showed that CsA-treatment
results in a 60% increase in the number of granules in juxtaglo-
merular cells [24]. The increase in stained complexes seen here is
consistent with that observation and indicates a fourfold increase
in the size of juxtaglomerular cell mass, either as a result of
hyperplasia of pre-existing granulated cells or the metaplasic
conversion of smooth muscle cells.
The EM studies show that TGF-f3 is localized within the
secretion granules of juxtaglomerular cells both in CsA-treated
and control olive oil-treated rats, although staining intensities
varied from cell to cell. We have not undertaken a detailed
analysis of the number of gold particles per granules as we
consider this an unreliable form of quantification. Generally,
there seemed to be somewhat fewer particles per secretion
granule profile in the control olive oil-treated animals than in
CsA-treated ones. However, the major difference between control
and CsA-treated tissue was in the number of granulated juxtaglo-
merular cells per complex and the number of granules per cell.
Interactions between CsA and TGF-f3 have been described in
other mammalian cell lines where CsA regulates cell growth via a
TGF-13-dependent mechanism [38]. Cyclosporine has also been
shown to stimulate the synthesis of TGF-13 in human T lympho-
cytes [39]. In the kidney, other studies have shown that water
deprivation [251 or potassium depletion [26] are potent stimuli for
TGF-p expression within the juxtaglomerular apparatus. In this
study, however, there was no evidence of hypokalemia nor
increased TGF-J3 staining in pair-fed controls which had restricted
amounts of water. The fact that control ischemic kidneys showed
a comparable increase in juxtaglomerular arteriolar staining sug-
gests that CsA-induced renal ischemia may be the determinant
factor in the observed increase in arteriolar TGF-/3. This is
consistent with previous observations that renal artery stenosis in
human neonates results in increased expression of juxtaglomeru-
lar TGF-f3 [27].
In this study, we have identified the presence of TGF-/3 within
the secretion granules of the juxtaglomerular cells. We can only
Table 3. Intensity of staining of afferent and interlobular arterioles
N Weak Moderate Strong
Control 15 96 3 1
Pair-fed control 6 89 10 1
CsA,Smg/kg 3 78 19 3
CsA, 7.5 mg/kg 3 77 16 7
CsA, 10 mg/kg 3 39 37 24
CsA, 12.5 mg/kg 6 6 38 56
CsA, 25 mg/kg 12 9 19 79
Ischemia group 6
Left kidney 34 51 15
Right kidney 71 27 2
Results are expressed as percentage of total number of arterioles which
stained with TGF-p.
speculate, at this stage, as to the significance of this finding and its
relevance to CsA-induced renal morphological changes. It is
important to note, however, that this TGF-/3 is likely to be in an
inactive form as this growth factor is normally activated upon
secretion. Its localization within juxtaglomerular cells granules
suggests that it is released in parallel with the vasoactive peptides
produced by these cells. These observations also suggest that
TGF-/3 may contribute to the CsA-induced hypertrophy and
hypergranularity of the juxtaglomerular cells, whereas previously
this role has been variously ascribed to renin, angiotensin II and
most recently PDGF [24]. However, our finding is not inconsistent
with these previous reports since interactions are known to take
place between TGF-p, renin, angiotensin II and PDGF. For
example, in juxtaglomerular cells in culture, TGF-p stimulates
renin release [401, while in vascular smooth muscle cells angio-
tensin II has been shown to stimulate the release of TGF-13 [41].
Furthermore, interactions between TGF-/3 and PDGF in vascular
smooth muscle cells determine the nature of the growth response
(hypertrophy or hyperplasia) of these cells to angiotensin II in
vitro [421. Such interactions between TGF-/3 and other growth
promoters present within the juxtaglomerular cells may be instru-
mental in the hypertrophy of juxtaglomerular cells observed in
CsA-treated rats.
TGF-p is also a well-known renal fibrogenic growth factor [43].
It has been shown to mediate the deposition of excess extracellu-
lar matrix proteins by mesangial cells in experimental [44] and
human [45] glomerular diseases. Further, the transfection of rat
glomeruli with the TGF-pl gene leads to glomerulosclerosis [46].
Treatment of rats with experimental glomerulonephritis with a
neutralizing anti-TGF-f31 antibody [47] or with a natural antago-
nist to TGF-f3 [48] confirmed a causal role for this growth factor
in the pathogenesis of glomerulosclerosis. In view of the similarity
between juxtaglomerular and mesangial cells [49], it is conceivable
that TGF-f3 is also responsible for CsA-induced interstitial fibro-
sis. This may depend on paracrine interactions within the kidney.
In conclusion, our observation establishes an association be-
tween TGF-/3 and CsA-induced nephrotoxicity. It suggests that
the observed changes in renal TGF-f3 may be linked to CsA-
induced renal ischemia. However, confirmation of a causal link
between TGF-13, renal ischemia and CsA-induced nephrotoxicity
will depend on further studies, similar to those described above,
and based on the manipulation of TGF-f3.
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Fig. 3. Immunocytochemist,y of TGF-13 using 10 nm colloidal gold probes-CsA, 12.5 mg/kg/day. A. Survey electron micrograph showing hypertrophied
juxtaglomerular cells with enlarged secretory granules labeled with colloidal gold (X 5,900). B. Portion of hypertrophied juxtaglomerular cells showing
heavily labeled secretory granules. Note that the colloidal gold is confined to the granules, with no staining of the intervening cytoplasm (X 46,000). C.
Control tissue showing lower density of labeling of the granules of the juxtaglomerular cell (x 37,000). D. CsA-treated tissue incubated with
non-immune goat serum in place of TGF-j3 antibody showing no gold particles over the secretion granules of the juxtaglomerular cells (x 14,100). E.
CsA-treated tissue incubated with goat anti-human collagen type IV antibody showing labeling of fibers in the extracellular matrix but no labeling of
secretion granules (inappropriate antibody) (X 15,800). F. Tissue from left (ischemic) kidney of a rat subjected to unilateral renal ischemia. A pattern
and intensity of labeling similar to that of CsA-treated tissue is evident (x 18,500).
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Fig. 4. Northern blot analysis of rat kidney total
RNA, hybridized with a 32P labeled TGF-
j31cDNA. A. Left panel, CsA 12.5 mg/kg/day;
right panel, olive oil control; upper panel, TGF-
/31; lower panel, loading controls showing 28 s
and 18 s RNA. B. Optical density of TGF-f31
2 3 4 5 6 7 8 9 mRNA of each animal.
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Glomerular profiles
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Periglomerular arterioles
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1.48 0.06
1.52 0.07
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0.81 0.07"
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0.21 0.08
CsA, 10 mg/kg
CsA, 12.5 mg/kg
CsA, 25 mg/kg
3C
6C
l2
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1.51 0.12
1.46 0.07
1.18 0.12C
0.84 0.15"
1.12 0.10C
0.34 0.12
0.31 0.02
0.39 0.08"
Ischemia group 6
Left kidney 4.73 0.31 1.20 0.04 0.78 0.09 0.19 0.06
Right kidney 5.94 0.73 1.43 0.10 0.40 0.06a 0.09 0.O1C
Results are expressed as mean SEM.
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